SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.
Guggenheim SMID Cap Biotech Conference
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Wednesday, February 5 at 10:30 a.m. ET | |
| Location: | New York, NY | |
| Webcast link: | /webcast/guggen2/register.aspx?conf=guggen2&page=gpcr&url=https://wsw.com/webcast/guggen2/gpcr/2003892 | |
Leerink Global Healthcare Conference
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Monday, March 10 at 1:00 p.m. ET | |
| Location: | Miami, FL | |
| Webcast link: | /webcast/leerink38/register.aspx?conf=leerink38&page=gpcr&url=https://wsw.com/webcast/leerink38/gpcr/2218364 | |
Jefferies Biotech on the Bay Summit
| Format: | 1x1 meetings | |
| Date: | Tuesday, March 11 | |
| Location: | Miami, FL |
The live and archived webcasts of the fireside chats will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and replays will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Dan Budwick
1AB
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$69.80 |
| Daily Change: | 35.24 101.97 |
| Daily Volume: | 20,989,742 |
| Market Cap: | US$4.240B |
December 08, 2025 December 08, 2025 December 07, 2025 November 06, 2025 August 06, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
